Kyushu University Academic Staff Educational and Research Activities Database
List of Papers
Hideya Onishi Last modified date:2023.11.22

Associate Professor / Department of Cancer Therapy and Research / Department of Advanced Medical Initiatives / Faculty of Medical Sciences

1. Na L, Onishi H, Morisaki S, Ichimiya S, Yamada Y, Masuda S, Nagao S, Koga S, Nakayama K, Imaizumi A, Oda Y, Nakamura M, MAML3 contributes to induction of malignant phenotype of gallbladder cancer yhrough morphogenesis signaling under hypoxia, Anticancer Res, 43, 7, 2023.07.
2. Na L, Masuda S, Nagao S, Morisaki S, Iwamoto N, Sakanashi K, Onishi H, C4orf47 contributes to the induction of stem-like properties in gallbladder cancer under hypoxia, Anticancer Res , 10.21873/anticanres.16352.PMID: 37097647, 43, 5, 1925-1932, 2023.05.
3. Mei T, Noguchi H, Kuraji R, Kubo S, Sato Y, Kaku K, Okabe Y, Onishi H, Nakamura M, Effects of periodontal pathogen–induced intestinal dysbiosis on transplant immunity in an allogenic skin graft model, Sci Rep, 10.1038/s41598-023-27861-4, 13, 1, 544, 2023.01.
4. Nagao S, Onishi H, Kawamoto M, Masuda S, Na L, Morisaki S, Iwamoto N, Yamada Y, Koga S, Ichimiya S, Nakayama K, Imaizumi A, Nakashima K, Oda Y, Nakamura M, C4orf47 contributes to the dormancy of pancreatic cancer under hypoxic condition., J Cancer, 10.7150/jca.78993, 14, 2, 306-317, 2023.02.
5. Ozono K, Onishi H, Iwamoto N, Nakamura K, Miyoshi K, Nakamura M, Oda Y., Tropomyosin-related kinase B is a biomarker of prognosis and therapeutic target for malignant thymic epithelial tumors., Anticancer Res, 42, 3779-3787, 2022.11.
6. Onishi H, Iwamoto N, Sakanashi K, Koga S, Oyama Y, Yanai K, Nakamura K, Nagai S, Fujimura A, Nakayama K, Ozono K, Yamasaki A, PTPN3 could be a therapeutic target of pancreatic cancer, Anticancer Res, 2022.05.
7. Guan W, Nakata K, Sagara A, Endo S, Iwamoto C, Ikenaga N, Shindo K, Moriyama T, Matsuda R, Onishi H, Ohuchida K, Mizumoto K, Oda Y, Nakamura M, Erap2 affects pancreatic stellate cells activation via autophagy. , Pancreatology, 10.1016/j.pan.2021.09.012, 22, 1, 9-19, 2021.05.
8. Ichimiya S, Fujimura A, Masuda M, Masuda S, Yasumatsu R, Umebayashi M, Tanaka H, Koya N, Nakagawa S, Yoshimura S, Onishi H, Nakamura M, Nakamura Y, Morisaki T., Contribution of pre-existing neoantigen-specific T cells to durable complete responses after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma., Immunol Invest, 10.1080/08820139.2021.1973491, 2021.05.
9. Morisaki T, Morisaki T, Kubo M, Onishi H, Hirano T, Morisaki S, Eto M, Monji K, Takeuchi A, Nakagawa S, Tanaka H, Koya N, Umebayashi M, Tsujimura K, Yew PY, Yoshimura S, Kiyotani K, Nakamura Y, Efficacy of intranodal neoantigen peptide-pulsed dendritic cell vaccine monotherapy in patients for advanced solid tumors; retrospective analysis., Anticancer Res, 10.21873/anticanres.15213, 41, 8, 4101-4115, 2021.05.
10. Oyama Y, Nagao S, Na L, Yanai K, Umebayashi M, Nakamura K, Nagai S, Fujimura A, Nakayama K, Morisaki T, Onishi H, TrkB/BDNF signaling could be a new therapeutic target for pancreatic cancer, Anticancer Res, 10.21873/anticanres.15205, 41, 8, 4047-4052, 2021.05.
11. Koga S, Onishi H, Masuda S, Fujimura A, Ichimiya S, Nakayama K, Imaizumi A, Nishiyama K, Kojima M, Miyoshi K, Nakamura K, Umebayashi M, Morisaki T, Nakamura M, PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor., Transl Oncol, 10.1016/j.tranon.2021.101152, 14, 9, 101152, 2021.05.
12. Yuki Sekino, Akira Imaizumi, Noritaka Komune, Mayumi Ono, Kuniaki Sato, Shogo Masuda, Akiko Fujimura, Kensuke Koike, Takahiro Hongo, Ryutaro Uchi, Hideya Onishi, Takashi Nakagawa, Establishment and characterization of a primary cell culture derived from external auditory canal squamous cell carcinoma., FEBS open Bio, 10.3892/or.2021.7947, 11, 2211-2224, 2021.05.
13. Ichimiya S, Onishi H, Nagao S, Koga S, Sakihama K, Nakayama K, Fujimura A, Oyama Y, Imaizumi A, Oda Y, Nakamura M, GLI2 but not GLI1/GLI3 plays a central role in the induction of malignant phenotype of gallbladder cancer, Oncol Rep, 10.3892/or.2021.7947, 2021.05.
14. Nakayama K, Onishi H, Fujimura A, Imaizumi A, Kawamoto M, Oyama Y, Ichimiya S, Koga S, Fujimoto Y, Nakashima K, Nakamura M, NFkB and TGFb contribute to the expression of PTPN3 in activated human lymphocytes., Cell Immunol, 10.1016/j.cellimm.2020.104237, 2020.08.
15. Morisaki T, Hikichi T, Onishi H, Morisaki T, Kubo M, Hirano T, Yoshimura S, Kiyotani K, Nakamura Y, Intranodal administration of neoantigen peptide-loaded dendritic cell vaccine elicits epitope-specific T cell responses and clinical effects in a patient with chemorefractory ovarian cancer with malignant ascites, Immunol Invest, 2020.12.
16. Saeki K, Onishi H, Koga S, Ichimiya S, Nakayama K, Oyama Y, Kawamoto M, Sakihama K, Yamamoto T, Matsuda R, Miyasaka Y, Nakamura M, Oda Y, FAM115C could be a novel tumor suppressor associated with prolonged survival in pancreatic cancer patients, J Cancer, doi: 10.7150/jca.38399, 11, 8, 2289-2302, 2020.08.
17. Oyama Y, Onishi H, Koga S, Murahashi M, Ichimiya S, Nakayama K, Fujimura A, Kawamoto M, Imaizumi A, Umebayashi M, Ohuchida K, Morisaki T, Nakamura M, Patched 1-interacting peptide represses fibrosis in pancreatic cancer to augment the effectiveness of immunotherapy., J Immunother, doi: 10.1097/CJI.0000000000000305, 43, 4, 121-133, 2020.04.
18. Fujimura A, Nakayama K, Imaizumi A, Kawamoto M, Oyama Y, Ichimiya S, Umebayashi M, Koya N, Morisaki T, Nakagawa T, Onishi H, PTPN3 expressed in activated T lymphocytes is a candidate for a non-antibody type immune checkpoint inhibitor., Cancer Immunol Immunother, 10.1007/s00262-019-02403-y, 68, 10, 1649-1660, 2019.10.
19. Onishi H, Yamasaki A, Nakamura K, Ichimiya S, Yanai K, Umebayashi M, Nagai S, Morisaki T, Liprin-alpha4 as a new therapeutic target for SCLC as an upstream mediator of HIF1, Anticancer Res, 2019.03.
20. Nakamura S, Sadakari Y, Ohtsuka T, Okayama T, Nakashima Y, Gotoh Y, Saeki K, Mori Y, Nakata K, Miyasaka Y, Onishi H, Oda Y, Goggins M, Nakamura M, Pancreatic juice exosomal microRNAs as sensitive biomarkers for detection of pancreatic ductal adenocarcinoma., Ann Surg Oncol, 2019.01.
21. Onishi H, Ichimiya S, Yanai K, Umebayashi M, Nakamura K, Yamasaki A, Imaizumi A, Nagai S, Murahashi M, Ogata H, Morisaki T, RBPJ and MAML3: Potential therapeutic targets for small cell lung cancer., Anticancer Res, 2018.08.
22. Kawamoto M, Ozono K, Oyama Y, Yamasaki A, Oda Y, Onishi H, The novel selective pan-TRK inhibitor ONO-7579 exhibits antitumor efficacy against human gallbladder cancer in vitro., Anticancer Research, 38, 4, 1979-1986, 2018.04.
23. Yamasaki A, Nakayama K, Imaizumi A, Kawamoto M, Fujimura A, Oyama Y, Nagai S, Yanai K, Onishi H, Liprin-4 as a possible new therapeutic target for pancreatic cancer., Anticancer research, 37, 12, 6649-6654, 2017.12.
24. Hideya Onishi, Akiko Fujimura, Yasuhiro Oyama, Akio Yamasaki, Akira Imaizumi, Makoto Kawamoto, Mitsuo Katano, Masayo Umebayashi, Takashi Morisaki, Hedgehog signaling regulates PDL-1 expression in cancer cells to induce anti-tumor activity by activated lymphocytes. , Cell Immunol, 2017.05.
25. Hideya Onishi, Kumi Suyama, Akio Yamasaki, Yasuhiro Oyama, Akiko Fujimura, Makoto Kawamoto, Akira Imaizumi, CD24 Modulates Chemosensitivity of MCF-7 Breast Cancer cells., Anticancer Res, 2017.02.
26. Katsuya Nakamura, Kei Miyoshi, Hideya Onishi, Future view of safe, painless and curative video assisted thoracoscopic surgery for lung cancer., Video-assist Thorac Surg. , 2016.08.
27. Keigo Ozono, Yoshihiro Ohishi et al., Hideya Onishi, Katsuya Nakamura, Junichi Motoshita, Masato Kato, Nakanishi Y, Masafumi Nakamura, Yoshinao Oda, Brain-derived neurotrophic factor / tropomyosin-related kinase B signaling pathway contributes to the aggressive behavior of lung squamous cell carcinoma., Lab Invest, 2017.05.
28. Makoto Kawamoto, Hideya Onishi, Keigo Ozono, Akio Yamasaki, Akira Imaizumi, Sachiko Kamakura, Kenji Nakano, Yoshinao Oda, Hideki Sumimoto, Masafumi Nakamura, Tropomyosin-related kinase B mediated signaling contributes to the induction of malignant phenotype of gallbladder cancer., Oncotarget, 2017.05, Purpose: BDNF/TrkB signaling has been shown to be associated with aggressive phenotype in some cancers, but has not yet been investigated in gallbladder cancer (GBC). This study aims to analyze the biological significance of BDNF/TrkB signaling in GBC, and explore its potential as a novel therapeutic target.
Experimental Design: We investigated TrkB expression clinically in 69 resected primary GBC specimens, and examined the correlation between TrkB expression and clinicopathological findings by immunohistochemistry. We used five TrkB-expressing GBC cell lines with or without K-ras mutation for in vitro investigations, and analyzed tumorigenesis and tumor growth of TrkB siRNA-transfected GBC cells in vivo using a xenograft model.
Results: TrkB expression was detected in 63 (91.3%) clinical GBC specimens. TrkB expression in the invasive front correlated with T factor (p=0.0391) and clinical staging (p=0.0391). Overall survival was lower in patients with high TrkB expression in the invasive front than in those with low TrkB expression (p=0.0363). In vitro, proliferation was unaffected by rhBDNF treatment; however, K252a treatment and TrkB siRNA transfection decreased proliferation. rhBDNF treatment increased invasiveness by inducing EMT and activating MMP-2/MMP-9, whereas K252a treatment abrogated these effects. TrkB or BDNF siRNA transfection suppressed invasiveness. TrkB siRNA transfection decreased HIF-1α, VEGF-A, and VEGF-C/-D expression. In vivo, TrkB siRNA transfection decreased tumorigenicity and tumor growth in GBC.
Conclusions: These findings demonstrate that TrkB-mediated signaling is associated with malignant phenotypes (proliferation, invasiveness, angiogenesis, lymphangiogenesis, and tumorigenesis) in GBC, and could be a novel therapeutic target regardless of K-ras mutation status..
29. Imaizumi A, Hideya Onishi, Yamasaki A, Kawamoto M, 森崎 隆, Goto M, Iwama M, Akaike T, Hasumi K, Sugar-carrying polystyrenes facilitate harvesting APCs from MLRs: Possible application of sugar-carrying polystyrenes to immunotherapy. , Anticancer Res, 36, 2, 673-676, 2016.02.
30. Imaizumi A, Hideya Onishi, Yamasaki A, Kawamoto M, Umebayashi M, 森崎 隆, Hasumi K, Hypoxic Conditions Promote Gemcitabine Sensitivity in a Pancreatic Cancer Stem Cell Line., Anticancer Res, 36, 2, 653-657, 2016.02.
31. Shinkai K, Kenji Nakano, Cui L, Mizuuchi Y, Hideya Onishi, Yoshinao Oda, Obika S, Masao Tanaka, Mitsuo Katano, Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and metastasis in mice tumor models., Int J Cancer, 2016.05.
32. Suyama K, Hideya Onishi, Imaizumi A, Shinkai K, Umebayashi M, Makoto Kubo, Mizuuchi Y, Yoshinao Oda, Masao Tanaka, Masafumi Nakamura, Mitsuo Katano, CD24 suppresses malignant phenotype by downregulation of SHH transcription through STAT1 inhibition in breast cancer cells. , Cancer Lett, 374, 1, 44-53, 2016.01.
33. Hideya Onishi, Yamasaki A, Kawamoto M, Imaizumi A, Mitsuo Katano, Hypoxia but not normoxia promotes Smoothened transcription through upregulation of RBPJ and Mastermind-like 3 in pancreatic cancer., Cancer Lett, 371, 2, 143-150, 2016.02.
34. Kato M, Hideya Onishi, Furugaki K, Yunotani S, Matsumoto K, Tsuruta N, Nakamura K, Mitsuo Katano, New approach to complete video-assisted thoracoscopic lobectomy in T2 and T3 non-small cell lung cancer., Anticancer Res, 35, 6, 3585-3589, 2015.06.
35. 森崎 隆, Hirano T, Koya N, Kiyota A, Tanaka H, Umebayashi M, Hideya Onishi, Mitsuo Katano, NKG2D-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors., Anticancer Res, 34, 8, 4529-4538, 2014.08.
36. Umebayashi Masayo, Kiyota Akio, Koya Norihiro, Tanaka Hiroto, Hideya Onishi, Mitsuo Katano, 森崎 隆, An epithelial cell adhesion molecule- and CD3 bispecific antibody plus activated T-cells can eradicate chemoresistant cancer stem-like pancreatic carcinoma cells in vitro., Anticancer Res, 34, 8, 4509-4520, 2014.08.
37. Hideya Onishi, 住吉 金次郎, 寺坂 禮治, Mitsuo Katano, Surgical Treatment to Aid Patients with Colorectal Perforation, In vivo, 28, 5, 997-1000, 2014.09.
38. Hideya Onishi, Akio Kiyota, Norihiro Koya, Hiroto Tanaka, Masayo Umebayashi, Mitsuo Katano, 森崎 隆, Random Migration Contributes to Cytotoxicity of Activated CD8+ T-Lymphocytes but not NK cells., Anticancer Res, 2014.08.
39. Masato Kato, Hideya Onishi, Kotaro Matsumoto, Junichi Motoshita, Nobuko Tsuruta, Kazuyoshi Higuchi, Mitsuo Katano, Prognostic Significance of Urine N1,N12-Diacetylspermine in Patients with Non-small Cell Lung Cancer., Anticancer Res, 2014.06.
40. Shojiro Matsushita, Hideya Onishi, Kenji Nakano, Iori Nagamatsu, Akira Imaizumi, Masami Hattori, Yoshinao Oda, Masao Tanaka, Mitsuo Katano, Hedgehog signaling pathway is a potential therapeutic target for gallbladder cancer., Cancer Sci, 105, 3, 272-280, 2014.03.
41. Iori Nagamatsu, Hideya Onishi, Shojiro Matsushita, Makoto Kubo, Masaya Kai, Akira Imaizumi, Kenji Nakano, Masami Hattori, Yoshinao Oda, Masao Tanaka, Mitsuo Katano, NOTCH4 is a potential therapeutic target for triple-negative breast cancer., Anticancer Res, 34, 1, 69-80, 2014.01.
42. Yoshihiro Morifuji, Hideya Onishi, Hironori Iwasaki, Akira Imaizumi, Kenji Nakano, Masao Tanaka, Mitsuo Katano, Reoxygenation from chronic hypoxia promotes metastatic processes in pancreatic cancer through the Hedgehog signaling., Cancer Science, 10.1111/cas.12348, 105, 3, 324-333, 2014.03.
43. Seiichi Odate, Hideya Onishi, Katsuya Nakamura, Masayuki Kojima, Akihiko Uchiyama, Masato Kato, Mitsuo Katano, Tropomyosine related kinase B inhibitor has potential for tumor regression and relapse prevention in pulmonary large cell neuroendocrine carcinoma. , Anticancer Res, 2013.09.
44. Hideya Onishi, Takashi Morisaki, A Kiyota, N Koya, H Tanaka, M Umebayashi, Mitsuo Katano, The Hedgehog inhibitor suppresses the function of monocyte-derived dendritic cells from patients with advanced cancer under hypoxia., Biochem Biophys Res Commun., 2013.08.
45. Takashi Morisaki, M Umebayashi, A Kiyota, N Koya, H Tanaka, Hideya Onishi, Mitsuo Katano, Combining celecoxib with sorafenib synergistically inhibits hepatocellular cells in vitro., Anticancer Res, 33, 4, 1387-1395, 2013.04.
46. Hideya Onishi, Takashi Morisaki, A Kiyota, N Koya, H Tanaka, M Umebayashi, Mitsuo Katano, The Hedgehog inhibitor cyclopamine impairs the benefits of immunotherapy with activated T and NK lymphocytes derived from patients with advanced cancer. , Cancer Immunol Immunother, 2013.08.
47. Hideya Onishi, Takafumi Morisaki, F Nakao, Seiichi Odate, Takashi Morisaki, Mitsuo Katano, Protein-bound polysaccharide decreases invasiveness and proliferation in pancreatic cancer by inhibition of hedgehog signaling and HIF-1 pathways under hypoxia. , Cancer Lett, 2013.07.
48. Seiichi Odate, Katsuya Nakamura, Hideya Onishi, Masayuki Kojima, Y Uchiyama, Kenji Nakano, Masato Kato, TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell meuroendocrine carcinoma. , Lung Cancer, 79, 3, 205-214, 2013.03.
49. Hironori Iwasaki, Kenji Nakano, Kentaro Shinkai, Y Kunisawa, M Hirahashi, Yoshinao Oda, Hideya Onishi, Mitsuo Katano, Hedgehog Gli3 activator signal augments tumorigenicity of colorectal cancer via up-regulation of adherence-related genes., Cancer Sci, 104, 3, 328-336, 2013.03.
50. Hiroyuki Suzuki, Hideya Onishi, Takashi Morisaki, Masao Tanaka, Mitsuo Katano, Intratumoral FOXP3+VEGFR2+ Regulatory T Cells Are Predictive Markers for Recurrence and Survival in Patients with Colorectal Cancer., Clin Immunol, 26-33, 2013.01.
51. Masato Kato, Hideya Onishi, Kotaro Matsumoto, Nobuko Tsuruta, Kazuyuki Higuchi, Juniichi Motoshita, Mitsuo Katano, Preoperative Chemoradiotherapy Using Cisplatin plus S-1
Can Induce Downstaging in Patients with Locally Advanced (Stage III) Non-Small-Cell Lung Cancer.
, Anticancer Res, 5099-5104, 2012.11.
52. Kubo M*, Onishi H*, Kuroki S, Okido M, Shimada K, Yokohata K, Umeda S, Ogawa T, Tanaka M, Katano M. (Co-contributor), Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer., Anticancer Res, 32, 6, 2331-2336, 2012.06.
53. Onishi H, Koya N, Kiyota A, Tanaka H, Umebayashi M, Katano M, Morisaki T., A new method for rapid cytotoxic T-lymphocyte induction using a multiple cytokine cocktail., Anticancer Res, 32, 6, 2385-2390, 2012.06.
54. Morisaki T, Umebayashi M, Kiyota A, Koya N, Tanaka H, Onishi H, Katano M., Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro. , Anticancer Res, 32, 6, 2249-2256, 2012.06.
55. Hideya Onishi, Yoshihiro Morifuji, Masaya Kai, Kumi Suyama, Hironori Iwasaki, Mitsuo Katano, Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic condition in pancreatic cancer, Cancer Sci, 2012.10.
56. Ogino T, Onishi H, Suzuki H, Morisaki T, Tanaka M, Katano M, Inclusive estimation of complex antigen presentation functions of monocyte-derived dendritic cells differentiated under normoxia and hypoxia conditions., Cancer Immunol Immunother, 61, 3, 409-424, 2012.03.
57. Kai M, Onishi H, Souzaki M, Tanaka H, Kubo M, Tanaka M, Katano M. , Semi-quantitative evaluation of CD44(+) /CD24(-) tumor cell distribution in breast cancer tissue by a newly developed fluorescence immunohistochemical staining method., Cancer Sci, 102, 12, 2132-2138, 2011.12.
58. Morisaki T*, Onishi H*, Koya N, Kiyota H, Tanaka M, Umebayashi M, Ogino T, Nagamatsu I, Katano M(* Co-contributor), Combinational cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA/B system. , Anticancer Res, 2011.07.
59. Yamasaki A*, Onishi H*, Morisaki T, Katano M (* Co-cntributor), Induction of cytotoxic T lymphocytes by CEA peptide-pulsed gamma-delta T cells isolated from patients with advanced cancer., Anticancer Res, 2011.07.
60. Kitaura Y, Chikazawa N, Tasaka T, Nakano K, Tanaka M, Onishi H, Katano M., Transforming Growth Factor β1 Contributes to the Invasiveness of Pancreatic Ductal Adenocarcinoma Cells Through the Regulation of CD24 Expression., Pancreas, 2011.09.
61. Xu R, Nakano K, Iwasaki H, Kumagai M, Wakabayashi R, Yamasaki A, Suzuki H, Mibu R, Onishi H, Katano M, Dual blockade of phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer., Cancer Lett, 306, 2, 151-160, 2011.07.
62. Souzaki M, Kubo M, Kai M, Kameda C, Tanaka H, Taguchi T, Tanaka M, Onishi H, Katano M, Hedgehog signaling pathway mediates the progression of non-invasive breast cancer to invasive breast cancer., Cancer Sci, 102, 373-381, 2011.02.
63. Tasaka T, Akiyoshi T, Yamaguchi K, Tanaka M, Onishi H, Katano M:, Gamma-secretase complexes regulate the responses of human pancreatic ductal adenocarcinoma cells to taxanes., Anticance Res, 30, 4999-5010, 2010.12.
64. Wada J*, Onishi H*, Suzuki H, Yamasaki A, Nagai S, Morisaki T, Katano M (* co-contributor), Surface-bound TGF-beta1 on effusion-derived exosomes participates in the maintenance of both number and suppressive function of regulatory T cells in malignant effusions., Anticancer Res, 30, 9, 3747-3757, 2010.09.
65. Chikazawa N, Tanaka H, Tasaka T, Nakamura M, Tanaka M, Onishi H, Katano M. , Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells., Anticancer Res, 30, 6, 2041-2048, 2010.06.
66. Onishi H, Kai M, Odate S, Iwasaki H, Morifuji Y, Ogino T, Morisaki T, Nakashima Y, Katano M:, Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer. , Cancer Sci., 2011.06.
67. Kameda C, Nakamura M, Tanaka H, Yamasaki A, Kubo M, Tanaka M, Onishi H, and Katano M, Estrogen receptor α (ER α) contributes to the regulation of hedgehog signaling pathway in ER α positive gastric cancer., Brt J Cancer, 102, 738-747, 2010.02.
68. Yamasaki A, Kameda C, Xu R, Tanaka H, Tasaka T, Chikazawa N, Suzuki H, Morisaki T, Kubo M, Onishi H, Tanaka M, Katano M, Nuclear factor kappaB-activated monocytes contribute to pancreatic cancer progression through the production of Shh. Cancer immunol. Immunother., Cancer immunol. Immunother., 59, 5, 675-686, 2010.05.
69. Suzuki H, Chikazawa N, Tasaka T, Wada J, Yamasaki A, Kitaura Y, Sozaki M, Tanaka M, Onishi H, Morisaki T, Katano M, Intratumoral CD8+T/FOXP3+ cell ratio is a predictive marker for survival in patients with colorectal cancer., Cancer Immunol. Immunother., 59, 5, 653-661, 2010.05.
70. Ikebe M, Kitaura Y, Nakamura M, Tanaka H, Yamasaki A, Nagai S, Wada J, Yanai K, Koga K, Sato N, Kubo M, Tanaka M, Onishi H, Katano M, Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer cells through the TLR4/MyD88 signaling pathway., J. Surg. Oncol, 100, 8, 725-731, 2009.12.
71. Suzuki H*, Onishi H*, Wada J, Yamasaki A, Tanaka H, Nakano K, Morisaki T, Katano M (* co-contributor), VEGFR2 is selectively expressed by FOXP3highCD4+ Treg., Eur. J, Immunol., 40, 197-203, 2010.01.
72. Onishi H, Kuroki H, Matsumoto K, Baba E, Kuga H, Tanaka M, Katano M, Morisaki T, Dysfunctional and short-lived subsets in monocyte-derived dendritic cells from patients with advanced cancer., Clinical Immunology 105:286-295, 2002, 10.1006/clim.2002.5293, 105, 3, 286-295, 2002.12.
73. Onishi H, Kuroki H, Matsumoto K, Baba E, Sasaki N, Kuga H, Tanaka M, Katano M, Morisaki T, Monocyte-derived dendritic cells that capture dead tumor cells secrete IL-12 and TNF-? through IL-12/TNF-?/NF-?B autocrine loop., Cancer Immunol Immunother 53:1093-1100, 2004, 10.1007/s00262-004-0568-y, 53, 12, 1093-1100, 2004.12.
74. Onishi H, Morisaki T, Kuroki H, Matsumoto K, Baba E, Kuga H, Tanaka M, and Katano M:, Evaluation of a dysfunctional and short-lived subset of monocyte-derived dendritic cells from cancer patients., Anticancer Res 25(5):3445-51, 2005, 25, 5, 3445-3451, 2005.09.
75. Morisaki T, Matsumoto K, Kuroki H, Kubo M, Baba E, Onishi H, Tasaki T, Nakamura M, Inaba S, Katano M, Combined immunotherapy with intracavital injection of activated lymphocytes, monocyte-derived dendritic cells and low-dose OK-432 in patients with malignant effusion. , Anticancer Res 23:4459-4465,2003, 23, 6A, 4459-4465, 2003.11.
76. Kuroki H, Morisaki T, Matsumoto K, Onishi H, Baba E, Tanaka M, Katano M:, OK-432, a streptococcal preparation, is a new maturation factor of monocyte-derived dendritic cells for clinical use., Cancer Immunology Immunotherapy 52:561-568,2003, 52, 561-568, 2003.09.
77. Kubo M, Morisaki T, Tasaki T, Kuroki H, Matsumoto K, Onishi H, Baba E, Katano M, Possible combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer., Anticancer Res 23:4443-4450, 2003, 23, 4443-4450, 2003.11.
78. Kuga H, Morisaki T, Nakamura K, Onishi H, Uchiyama A, Noshiro H, Tanaka M, Katano M:, Interferon-? suppresses transforming growth factor-?? -induced invasion of gastric carcinoma cells through cross-talk of Smad pathway in a three-dimensional culture model., Oncogene 22:7838-7847,2003, 10.1038/sj.onc.1207046, 22, 49, 7838-7847, 2003.10.
79. Tasaki A, Yamanaka N, Kubo M, Matsumoto K, Kuroki H, Nakamura K, Nakahara C, Onishi H, Kuga H, Baba E, Tanaka M, Morisaki T, Katano M: , Three-dimensional two-layer collagen matrix gel culture model for evaluating complex biological functions of monocyte-derived dendritic cells. , J Immunol Methods 287:79-90,2004, 10.1016/j.jim.2004.01.014, 287, 1-2, 79-90, 2004.04.
80. Kuga H, Morisaki T, Nakamura K, Onishi H, Matsuda T, Sueishi K, Tanaka M, Katano M:, Construction of a transplantable tissue-engineered artificial peritoneum., Eur Surg Res 36:323-330,2004, 10.1159/000079919, 36, 1-2, 323-330, 2004.09.
81. Matsumoto K, Morisaki T, Kubo M, Kuroki H, Onishi H, Nakamura K, Nakahara C, Kuga H, Baba E, Nakamura M, Hirata K, Tanaka M, Katano M., Exosomes secreted from monocyte-derived dendritic cells support in vitro na?ve CD4+ T cell survival through NF-?B activation., Cell Immunol 231:20-29, 2004, 10.1016/j.cellimm.2004.11.002, 231, 1-2, 20-29, 2004.09.
82. Katano M, Morisaki T, Koga K, Nakamura M, Onishi H, Matsumoto K, Tasaki A, Nakashima H, Akiyoshi T, Nakamura M, Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas., Anticancer Res Nov-Dec;25(6A):3771-6, 2005, 25, 6A, 3771-3776, 2005.11.